ReCAP

Management of Heart Failure in Patients With Type 2 Diabetes Dr Deepak Bhatt discusses data from EMPA-KIDNEY, SCORED, and SOLOIST showing benefit from sodium-glucose cotransporter 2 inhibitors in management of patients with heart failure and type 2 diabetes.
February 06, 2023
Best Practices in HR+/HER2- Breast Cancer Leading oncologists discuss best practices in treatment of HR+/HER2- breast cancer, including use of trastuzumab deruxtecan in metastatic disease and adjuvant abemaciclib in early-stage disease.
January 31, 2023
Improving Outcomes in Mantle Cell Lymphoma Dr Ann LaCasce from the Dana-Farber Cancer Center reviews new and emerging therapies for patients with relapsed/refractory mantle cell lymphoma, including CAR T-cell therapy and bispecific antibodies.
January 31, 2023
Advanced/Metastatic HER2+ Treatment Options and Rationale Dr Adam Brufsky discusses recommended frontline therapy and subsequent options for metastatic HER2+ breast cancer, including drugs active against central nervous system and brain metastases.
January 31, 2023
Key Advances in Acute Myeloid Leukemia From ASH 2022 Key data on induction therapy, the optimal duration of venetoclax doublet treatment, and novel menin inhibitors top the acute myeloid leukemia highlights from ASH 2022 chosen by Dr Harry Erba.
January 30, 2023
CD19-Directed CAR-T-Cell Therapy in Relapsed/Refractory BCL Leading oncologists discuss recent trials examining CAR T-cells as second-line treatment in patients with relapsed/refractory B-cell lymphoma and raise questions on optimal use and patient selection.
January 27, 2023
Optimal Treatment for Active SLE Drs Joan Merrill and Anca Askanase discuss treatment options for active systemic lupus erythematosus (SLE), including biologics anifrolumab and belimumab, as well as optimal selection and timing of therapy.
January 17, 2023
Treatment Advances in Paroxysmal Nocturnal Hemoglobinuria Up to 40% of patients with paroxysmal nocturnal hemoglobinuria have inadequate response to C5 inhibition. Dr Catherine Broome discusses current and developing alternatives for clinicians to consider.
January 11, 2023
Targeted Therapies for Triple-Negative Breast Cancer Drs Tripathy and Yam discuss new therapeutic options that can benefit patients with triple-negative breast cancer, including PD-1 inhibitors, PARP inhibitors, and Trop-2 antibody-drug conjugates.
December 23, 2022
Managing T2D Patients With Cardiorenal-Metabolic Syndrome Physicians discuss management options for patients with type 2 diabetes who have cardiorenal-metabolic syndrome, including the use of SGLT2 inhibitors and GLP-1 agonists.
December 21, 2022
Optimizing COVID-19 Treatment in Hospitalized Patients French infectious disease expert Karine Lacombe, MD, PhD, discusses current treatment of patients hospitalized with COVID-19 and the most effective early treatment strategies according to disease severity.
December 02, 2022
Therapeutic Approaches in Advanced Breast Cancer Dr Susan Domchek, from the University of Pennsylvania, discusses the importance of identifying molecular characteristics of metastatic breast cancers to inform the choice of treatment.
November 15, 2022
GLP-1 RA for Management of T2D and Heart Disease Glucagon-like 1 receptor agonists are guideline-recommended for patients with type 2 diabetes who have heart disease or are at high risk. Dr Vivian Fonseca explains their benefit and appropriate use
November 09, 2022
Expanded Treatment Options for Lupus Nephritis Dr Joan Merrill discusses standard of care for patients with lupus nephritis and how recently approved agents belimumab and voclosporin have expanded treatment options for a subset of LN patients.
November 08, 2022
Prevention and Management of Severe Hypoglycemia in T2D Severe hypoglycemia in T2D can be life-threatening, but new therapeutic options offer improved management. Preventive measures include favoring lowest-risk treatments and continuous glucose monitoring.
November 07, 2022
Chronic Kidney Disease in T2D: Early Diagnosis and Management The benefit of early testing for kidney function in patients with diabetes and the goals of treatment in patients with CKD is discussed by Dr Joseph Vassalotti of Mount Sinai Hospital.
November 04, 2022
Biomarker Measurements in HFrEF Dr James Januzzi discusses applications for biomarkers in patients with heart failure with reduced ejection fracture, focusing on B-type natriuretic peptide (BNP), N-terminal proBNP, and troponins.
November 01, 2022
Common Challenges in Treating Chronic Myeloid Leukemia Tyrosine kinase inhibitors have transformed the prognosis for chronic myeloid leukemia, but challenges such as treatment resistance and TKI intolerance remain and are addressed by Dr Ehab Atallah.
October 20, 2022
Treatment Advances in HR+/HER2- Metastatic Breast Cancer Treatment updates in HR+/HER2- breast cancer are discussed by Drs Nadia Harbeck and Alessandra Gennari, including overall survival improvements from CDK4/6 inhibitors and antibody-drug conjugates.
October 18, 2022
COVID-19 Booster Immunization Infectious disease experts from Vanderbilt University share advice for communicating with patients about COVID-19 booster immunization with new bivalent vaccines that target the Omicron variant.
October 17, 2022